secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001193125-25-291448
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned
--------------------------------------------------------------------------------

- Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.
- Decision based on not pursuing further development of CLN-617 cancer immunotherapy.
- Company will return licensed patent rights for CLN-617 technology to MIT.
- CLN-617 was an exclusive worldwide license for a cancer immunotherapy product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/0001193125-25-291448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/cgem-20251118.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-291448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer